Fig. 5
From: Long noncoding RNA MEG3 blocks telomerase activity in human liver cancer stem cells epigenetically
MEG3 inhibits the binding of POT1, ExoI, TRF2, and SNM1B to telomeric DNA and enhances the binding of CST/AAF to telomeric DNA in liver cancer stem cells. A The co-immunoprecipitated with anti-CST/AAF or anti-TRF2. The precipitates were analyzed by Western blotting with anti-POT1 or anti-SNM1B. IgG co-immunoprecipitation was used as a negative control. B (a) DNA pulldown assay using biotin-labeled telomere DNA probe (Biotin-telomere DNA) and then Western blotting with anti-POT1, anti-ExoI, anti-TRF2, anti-SNM1B, and anti-CST/AAF. B (b) Quantitative analysis of gray scales of positive bands. C Chromatin immunoprecipitation (CHIP) using anti-POT1, anti-ExoI, anti-TRF2, anti-SNM1B, and anti-CST/AAF. IgG chromatin immunoprecipitation was used as a negative control